The effect of topical cyclosporine A on tear film instability in patients with posterior blepharitis

Öz

Objective: The aim of this study is to evaluate the efficacy of topical cyclosporine A (CsA) 0.05% (Restasis, Allergan Pharmaceuticals) in patients with posterior blepharitis. Methods: The study included 15 patients with posterior blepharitis. Topical CsA 0.05% (Restasis, Allergan Pharmaceuticals) was applied twice a daily for 2 months. They were evaluated at baseline and after treatment for subjective symptoms and objective signs including tear breakup time (BUT), Schirmer scores, conjunctival hyperemia, tarsal telangiectasis and Meibomian gland inclusions. Results: Fifteen patients completed the study. At the 2-month visit, the patients showed improvement in ocular symptom including burning, itching, conjunctival hyperemia (p

Anahtar Kelimeler

• Posterior blepharitis, Cyclosporine A, Schirmer scores, breakup time

Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi

Öz

Amaç: Posterior blefaritli hastalarda topikal siklosporin A (CsA) tedavisinin etkinliğini değerlendirmek. Yöntemler: Posterior blefaritli 15 hasta çalışmaya dahil edildi. Hastalara 2 ay boyunca günde 2 kez topikal CsA %0.05 (Restasis, Allergan Pharmaceuticals) uygulandı. Hastalarda tedavi öncesi ve sonrası subjektif semptomlara ve gözyaşı kırılma zamanı (GKZ), Schirmer testi, konjonktival hiperemi, tarsal telenjiektazi ve meibomian bezi sekresyonuna bakıldı. Bulgular: 2 aylık takiplerde yanma, kaşıntı, konjonktival hiperemi semptomlarında azalma izlendi (Sırasıyla p

Anahtar Kelimeler

• Posterior blefarit, Siklosporin A, Schirmer testi, gözyaşı kırılma zamanı.

Kaynakça

1. Thygeson P. Etiology and treatment of blepharitis; a study in military personnel. Arch Ophthalmol 1946;36:445-457.
2. Moore CP. Immunomodulating agents. In: Ocular Therapeu- tics. Elsevier Inc. 2004;725–737.
3. Sall K, Stevenson OD, Mundorf TK et al. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000;107:631-639.
4. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclo- sporine in the treatment of vernal keratoconjunctivitis Am J Ophthalmol 1990;110:641-645.
5. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of li- pase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-1975.
6. Donshik P, Kulvin SM, Mckinley P, Skowron R. Treatment of chronic staphylococcal blepharoconjunctivitis with a new topical steroid anti-infective ophthalmic solution. Ann Ophthalmol 1983;15:162-167.
7. Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens 2003;29:96-99.
8. Foulks GN. Topical cyclosporine for treatment of ocular sur- face disease. Int Ophthalmol Clin 2006;46:105-122.

9. Salib G, McDonald M, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artifi cial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 2006;32:772–778.
10. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004;111:476-482.
11. Hom MM. The use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens 2006;32:109-111.
12. Hill JC. The use of systemic cyclosporin a in human corneal transplantation: a preliminary report. Documenta Ophthal- mol 1986;62:337-344.
13. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Ef- ficacy of commercially available topical cyclosporine a 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-175.
14. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 2006;22:47-53.